Clinical Trial

NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

Study acronym: NeoCARD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligible for anthracycline-based therapy due to underlying cardiac conditions.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-02-24; most recent amendment 2026-05-05.
Status change: Not Yet Recruiting → Recruiting 2025-10-20
Trial Details
NCT Number NCT06845319
Lead Sponsor Medical University of South Carolina
Conditions Triple Negative Breast Cancer
Enrollment 43 participants
Start Date 2025-10-20
Primary Completion 2027-10-20 (estimated)
Study Completion 2028-10-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-06